Therefore, high‐risk 11q‐deleted NB patients may preferentially benefit from the combination of anti‐GD2 immunotherapy with immune checkpoint inhibitors (i.e., anti‐PD‐L1, anti‐CTLA‐4, IDO1 inhibitors, etc.)to disable immune escape. The gene discussed is CTLA4; the disease is neuroblastoma.